SCHEMBL25928787

SCHEMBL25928787

Cc1ccccc1-c1cccc(NC(C)C)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.36
KDM4C Q9H3R0 1/20 0.36
TDP1 Q9NUW8 2/20 0.35
FFAR4 Q5NUL3 1/20 0.35
IDO1 P14902 1/20 0.35
NR4A2 P43354 1/20 0.35
MAPT P10636 5/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 3/20 0.34
HPGD P15428 2/20 0.34
GAA P10253 2/20 0.34
MALT1 Q9UDY8 1/20 0.34
LMNA P02545 1/20 0.34
ELANE P08246 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25928784 0.83 HTT (0.37) HTTKDM4CTDP1IDO1NR4A2
SCHEMBL4797007 0.83 IDO1 (0.44) HTTTDP1FFAR4IDO1MAPT
SCHEMBL17035490 0.75 ACHE (0.46) HTTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL30461968 0.75 MAPT (0.50) HTTTDP1IDO1MAPTKDM4E
SCHEMBL4750832 0.75 MAPT (0.50) HTTTDP1IDO1MAPTKDM4E
SCHEMBL17048148 0.74 TDP1 (0.38) TDP1FFAR4IDO1MEN1KMT2A
SCHEMBL18307723 0.73 GABRA1 (0.39) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL10393919 0.71 KEAP1 (0.48) HTTTDP1MAPTMEN1NPC1
SCHEMBL20655521 0.71 NR4A2 (0.45) TDP1IDO1NR4A2CYP1A2CYP3A4
SCHEMBL23102745 0.70 ALDH1A1 (0.35) HTTTDP1MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-11-09 US disclosed
US-11708351-B2 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708351-B2 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders CFD, TFPI, CFH HTT 2071/4885KDM4C 4183/4885TDP1 4535/4885
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, TFPI, CFH HTT 2071/4885KDM4C 4183/4885TDP1 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.